Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.
The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...
Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...
The American Hospital Association, Maine Hospital Association and four safety-net hospitals have filed a federal lawsuit to halt “unlawful” changes to the 340B drug pricing program, warning the shift ...
Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...
Zacks Investment Research on MSN
Pfizer (PFE) up 3.9% since last earnings report: Can it continue?
A month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Too many hospitals take advantage of 340B, intended to make medications affordable for low-income patients. A New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results